Gaucher Disease and Orthodontics UK

What is Gaucher disease and how does it affect the jaws?

Gaucher disease is an inherited metabolic condition caused by deficiency of the enzyme glucocerebrosidase, which is needed to break down a fatty substance called glucocerebroside inside lysosomes — the cell's recycling compartments. Without enough functioning enzyme, glucocerebroside accumulates inside macrophages, forming characteristic 'Gaucher cells' that build up in the bone marrow, spleen, liver, and, relevantly for orthodontics, within the jaw bones. It is the most common lysosomal storage disorder, though still rare overall, and type 1 (the non-neuronopathic form) is the type most commonly seen and managed long-term in UK adults and children. Infiltration of Gaucher cells into the marrow spaces of the maxilla and mandible can alter normal bone architecture, reduce bone density in affected regions, and in more advanced or poorly controlled cases produce a widened, thinned appearance of the long bones known as the Erlenmeyer flask deformity — a similar pattern of medullary expansion and cortical thinning can be reflected in jaw bone imaging.

Why jaw bone quality matters for orthodontic planning

Orthodontic tooth movement relies on healthy, responsive bone remodelling around the tooth roots — bone resorbing on one side of the tooth and forming on the other as the tooth moves through the alveolar bone. Where Gaucher cell infiltration has reduced bone density or altered marrow architecture in the jaws, the quality of that bone response can be less predictable, and some clinicians take a more cautious, closely monitored approach to force application as a result. This does not mean orthodontic treatment is unsafe in Gaucher disease, but it does mean baseline imaging and, where relevant, a discussion with the patient's metabolic specialist about current bone status (including any recent bone density or MRI findings, which are used to monitor Gaucher-related skeletal disease) is a sensible part of treatment planning, particularly for patients whose disease is not yet well controlled on enzyme replacement therapy.

Extraction and surgical risk: osteonecrosis and healing

Where tooth extraction is planned as part of an orthodontic treatment plan — commonly to create space in a crowded arch — patients with Gaucher disease warrant extra consideration. Reduced bone marrow blood supply in affected areas, a recognised feature of Gaucher bone disease, has been associated with impaired healing and a risk of osteonecrosis following surgical procedures including dental extraction, particularly in patients with more significant skeletal involvement. This risk should be discussed with the patient's Gaucher specialist before any extraction is carried out, and the extracting clinician should be made aware of the diagnosis so that surgical technique, follow-up, and monitoring for delayed healing can be adjusted accordingly. Where extractions can be avoided through alternative orthodontic strategies — such as interproximal enamel reduction or arch expansion instead of extraction-based space creation — this may be worth discussing as part of the treatment planning conversation, though the final decision depends on the specific malocclusion and what is achievable without extraction.

Bleeding risk from thrombocytopenia and coagulation factor changes

Gaucher disease frequently involves thrombocytopenia (low platelet count) as a result of splenic enlargement and bone marrow infiltration, and some patients also have reduced levels of certain clotting factors. This has direct relevance to any procedure involving bleeding — including tooth extraction, exposure of an impacted tooth, or even more minor gum trauma from an ill-fitting appliance. A current platelet count and coagulation profile should be checked before any invasive dental or orthodontic procedure, and the patient's haematology or metabolic team should be consulted where counts are low, since local measures (such as pressure and haemostatic dressings) or a short period of platelet support may be needed around surgery. For routine, non-surgical orthodontic care — fitting brackets, adjusting wires, placing aligners — the bleeding risk is much lower, but any bracket or wire causing repeated soft tissue trauma should be addressed promptly given the reduced ability to control bleeding if trauma becomes more significant.

Enzyme replacement therapy and its effect on bone quality over time

Enzyme replacement therapy (ERT) — most commonly imiglucerase, given as a regular intravenous infusion — is the mainstay of treatment for type 1 Gaucher disease in the UK, commissioned through NHS England's specialised services. ERT reduces glucocerebroside accumulation and, over months to years of consistent treatment, is associated with improvement in bone marrow infiltration and bone density in many patients. An oral substrate reduction therapy (eliglustat) is also used in some adults. For orthodontic planning, this means a patient's bone quality may genuinely improve over the course of their Gaucher treatment, and jaw bone status assessed at the start of orthodontic care may not reflect the picture a year or two later. Coordinating orthodontic timing with the patient's metabolic team — for example, considering whether bone status has stabilised or improved since starting or adjusting ERT — can support more predictable treatment planning, particularly for patients whose disease was previously poorly controlled.

Anaemia, fatigue, and appointment planning

Many patients with Gaucher disease experience anaemia, again related to bone marrow involvement and splenic enlargement, which can cause fatigue and reduced exercise tolerance. While this does not usually affect routine orthodontic appointments, it is worth factoring into appointment planning for longer or more involved procedures — extraction, surgical exposure of a tooth, or lengthy bonding appointments — where a patient with significant anaemia may need more frequent breaks or a shorter overall appointment. Anaemia can also affect wound healing to some degree, reinforcing the value of close coordination with the haematology or metabolic team before any surgical adjunct to orthodontic treatment.

Working with the Gaucher specialist and metabolic team

In the UK, Gaucher disease is managed through a small number of NHS-designated specialist centres under highly specialised commissioning, with patients typically under long-term follow-up from a metabolic medicine or haematology consultant. Before starting orthodontic treatment — and particularly before any extraction or surgical step — it is good practice for the orthodontist to request a summary from this specialist team covering current platelet count, recent bone imaging or density results, ERT or substrate reduction therapy status, and any specific precautions the team recommends. The Gaucher specialist can also advise on whether the patient's disease is considered well controlled, which has a direct bearing on how cautiously bone-dependent procedures such as extraction should be approached. Patients and families should feel able to bring this coordination up directly with their orthodontic team if it has not already been raised.

Useful related pages

This guide is for general information only. It is not a diagnosis, treatment plan, or substitute for advice from a registered dentist or orthodontist.